Published in Medical Imaging Week, September 17th, 2005
Under the terms of this agreement with the FDA, the company may conduct two smaller phase III trials, POET-1 and POET-2, rather than one large phase III trial without sacrificing its SPA status and will be permitted to include all subjects currently enrolled in the existing phase III clinical trial pursuant to the revised...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Imaging Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.